v3.21.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Product sales, net $ 2,924,707 $ 1,811,386
Cost of products sold 1,122,413 527,250
Gross profit 1,802,294 1,284,136
Selling, general and administrative expenses 2,749,299 2,748,043
Research and development expenses 16,444 107,480
Depreciation and amortization expense 20,924 37,219
Total operating expenses 2,786,667 2,892,742
Loss from operations (984,373) (1,608,606)
Interest expense, net (2,535) (4,097)
Loss before provision for income taxes and net of equity investments (986,908) (1,612,703)
Provision for income taxes (250) (250)
Loss before equity in net earnings of equity investments (987,158) (1,612,953)
Income from China Joint Venture 1,301
Net loss (985,857) (1,612,953)
Net loss attributable to noncontrolling interests (12,988) (12,738)
Net loss attributable to Milestone Scientific Inc. $ (972,869) $ (1,600,215)
Net loss per share applicable to common stockholders—    
Basic (in dollars per share) $ (0.01) $ (0.03)
Diluted (in dollars per share) $ (0.01) $ (0.03)
Weighted average shares outstanding and to be issued—    
Basic (in shares) 66,578,435 49,730,252
Diluted (in shares) 66,578,435 49,730,252

Source